# First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

> **NCT05427253** · PHASE1 · COMPLETED · sponsor: **Vicore Pharma AB** · enrollment: 80 (actual)

## Conditions studied

- Safety Issues
- Tolerance
- Idiopathic Pulmonary Fibrosis
- Pulmonary Hypertension

## Interventions

- **DRUG:** C106 solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05427253
- **Lead sponsor:** Vicore Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-08
- **Primary completion:** 2023-06-22
- **Final completion:** 2023-06-22
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05427253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05427253, "First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05427253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*